These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

642 related items for PubMed ID: 17681167

  • 1. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
    Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E, Niro V, Andriulli A, Leandro G, Di Mario F, Dallapiccola B.
    Gastroenterology; 2007 Aug; 133(2):465-71. PubMed ID: 17681167
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 6. CYP2C9*3 Loss-of-Function Allele Is Associated With Acute Upper Gastrointestinal Bleeding Related to the Use of NSAIDs Other Than Aspirin.
    Carbonell N, Verstuyft C, Massard J, Letierce A, Cellier C, Deforges L, Saliba F, Delchier JC, Becquemont L.
    Clin Pharmacol Ther; 2010 Jun; 87(6):693-8. PubMed ID: 20445534
    [Abstract] [Full Text] [Related]

  • 7. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
    Ma J, Yang XY, Qiao L, Liang LQ, Chen MH.
    J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
    [Abstract] [Full Text] [Related]

  • 8. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

  • 9. Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study.
    Vonkeman HE, Fernandes RW, van der Palen J, van Roon EN, van de Laar MA.
    Arthritis Res Ther; 2007 Apr; 9(3):R52. PubMed ID: 17521422
    [Abstract] [Full Text] [Related]

  • 10. A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin.
    Piazuelo E, Fuentes J, García-González MA, Jiménez P, Lanas A.
    Clin Ther; 2008 Jan; 30(1):121-30. PubMed ID: 18343248
    [Abstract] [Full Text] [Related]

  • 11. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 12. Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study.
    Labenz J, Peitz U, Köhl H, Kaiser J, Malfertheiner P, Hackelsberger A, Börsch G.
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):110-5. PubMed ID: 10363194
    [Abstract] [Full Text] [Related]

  • 13. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL, Silverstein FE, Agrawal NM, Hubbard RC, Kaiser J, Maurath CJ, Verburg KM, Geis GS.
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [Abstract] [Full Text] [Related]

  • 14. Aspirin-induced peptic ulcer and genetic polymorphisms.
    Shiotani A, Sakakibara T, Nomura M, Yamanaka Y, Nishi R, Imamura H, Tarumi K, Kamada T, Hata J, Haruma K.
    J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S31-4. PubMed ID: 20586862
    [Abstract] [Full Text] [Related]

  • 15. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].
    Márk L, Márki-Zay J, Fodor L, Kondacs A, Paragh G, Katona A.
    Orv Hetil; 2005 Apr 17; 146(16):739-43. PubMed ID: 15889670
    [Abstract] [Full Text] [Related]

  • 16. Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs.
    Biskupiak JE, Brixner DI, Howard K, Oderda GM.
    J Pain Palliat Care Pharmacother; 2006 Apr 17; 20(3):7-14. PubMed ID: 16931473
    [Abstract] [Full Text] [Related]

  • 17. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
    Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A.
    Clin Pharmacol Ther; 2004 Nov 17; 76(5):409-17. PubMed ID: 15536456
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S, Solomon DH, Wang PS, Rassen J, Brookhart MA.
    Arthritis Rheum; 2006 Nov 17; 54(11):3390-8. PubMed ID: 17075817
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 17; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
    Tàssies D, Freire C, Pijoan J, Maragall S, Monteagudo J, Ordinas A, Reverter JC.
    Haematologica; 2002 Nov 17; 87(11):1185-91. PubMed ID: 12414349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.